| Baseline characteristics . | All (n = 515) . |
|---|---|
| Demographics | |
| Age at implant (years), median (IQR) | 68.8 (59.6–75.4) |
| <50, n (%) | 45 (8.7) |
| 50–59, n (%) | 79 (15.3) |
| 60–69, n (%) | 130 (25.1) |
| 70–79, n (%) | 177 (34.4) |
| ≥ 80, n (%) | 84 (16.3) |
| Male sex, n (%) | 404 (78.5) |
| BMI (kg/m2), median (IQR) | 26.7 (24–30.5) |
| BMI < 18.5 kg/m2, n (%) | 14 (2.9) |
| BMI > 30 kg/m2, n (%) | 135 (28.2) |
| Ischemic cardiomyopathy | 275 (53.5) |
| Haemodialysis, n (%) | 3 (0.6%) |
| Comorbidities according to CCI criteria | |
| Diabetes mellitus, n (%) | 119 (23.1) |
| Arterial hypertension, n (%) | 284 (55.2) |
| Atrial fibrillation, n (%) | 156 (30.3) |
| CKD with eGFR < 60 mL/min/1.73 m2, n (%) | 192 (37.3) |
| History of acute myocardial infarction, n (%) | 206 (40) |
| Peripheral vascular disease, n (%) | 51 (9.1) |
| Cerebrovascular disease or TIA, n (%) | 28 (5.4) |
| Chronic obstructive pulmonary disease, n (%) | 46 (8.9) |
| Liver disease, n (%) | 15 (2.9) |
| Charlson Comorbidity Index, mean (SD) | 4.4 (2.3) |
| 0–2, n (%) | 108 (21) |
| 3–4, n (%) | 171 (33.2) |
| ≥ 5, n (%) | 236 (45.8) |
| Implanted device | |
| Single-chamber ICD, n (%) | 114 (22.1) |
| Dual-chamber ICD, n (%) | 165 (32) |
| CRT-D, n (%) | 198 (38.4) |
| Subcutaneous ICD, n (%) | 38 (7.4) |
| Primary prevention indication, n (%) | 376 (73) |
| Ejection fraction in %, median (IQR) | 33 (32–40) |
| Baseline characteristics . | All (n = 515) . |
|---|---|
| Demographics | |
| Age at implant (years), median (IQR) | 68.8 (59.6–75.4) |
| <50, n (%) | 45 (8.7) |
| 50–59, n (%) | 79 (15.3) |
| 60–69, n (%) | 130 (25.1) |
| 70–79, n (%) | 177 (34.4) |
| ≥ 80, n (%) | 84 (16.3) |
| Male sex, n (%) | 404 (78.5) |
| BMI (kg/m2), median (IQR) | 26.7 (24–30.5) |
| BMI < 18.5 kg/m2, n (%) | 14 (2.9) |
| BMI > 30 kg/m2, n (%) | 135 (28.2) |
| Ischemic cardiomyopathy | 275 (53.5) |
| Haemodialysis, n (%) | 3 (0.6%) |
| Comorbidities according to CCI criteria | |
| Diabetes mellitus, n (%) | 119 (23.1) |
| Arterial hypertension, n (%) | 284 (55.2) |
| Atrial fibrillation, n (%) | 156 (30.3) |
| CKD with eGFR < 60 mL/min/1.73 m2, n (%) | 192 (37.3) |
| History of acute myocardial infarction, n (%) | 206 (40) |
| Peripheral vascular disease, n (%) | 51 (9.1) |
| Cerebrovascular disease or TIA, n (%) | 28 (5.4) |
| Chronic obstructive pulmonary disease, n (%) | 46 (8.9) |
| Liver disease, n (%) | 15 (2.9) |
| Charlson Comorbidity Index, mean (SD) | 4.4 (2.3) |
| 0–2, n (%) | 108 (21) |
| 3–4, n (%) | 171 (33.2) |
| ≥ 5, n (%) | 236 (45.8) |
| Implanted device | |
| Single-chamber ICD, n (%) | 114 (22.1) |
| Dual-chamber ICD, n (%) | 165 (32) |
| CRT-D, n (%) | 198 (38.4) |
| Subcutaneous ICD, n (%) | 38 (7.4) |
| Primary prevention indication, n (%) | 376 (73) |
| Ejection fraction in %, median (IQR) | 33 (32–40) |
BMI, body mass index; CCI, Charlson Comorbidity Index; CKD, chronic kidney disease; CRT-D, cardiac resynchronization therapy and defibrillator; ICD, implantable cardioverter defibrillator; IQR, interquartile range; SD, standard deviation; TIA, transitory ischaemic attack.
| Baseline characteristics . | All (n = 515) . |
|---|---|
| Demographics | |
| Age at implant (years), median (IQR) | 68.8 (59.6–75.4) |
| <50, n (%) | 45 (8.7) |
| 50–59, n (%) | 79 (15.3) |
| 60–69, n (%) | 130 (25.1) |
| 70–79, n (%) | 177 (34.4) |
| ≥ 80, n (%) | 84 (16.3) |
| Male sex, n (%) | 404 (78.5) |
| BMI (kg/m2), median (IQR) | 26.7 (24–30.5) |
| BMI < 18.5 kg/m2, n (%) | 14 (2.9) |
| BMI > 30 kg/m2, n (%) | 135 (28.2) |
| Ischemic cardiomyopathy | 275 (53.5) |
| Haemodialysis, n (%) | 3 (0.6%) |
| Comorbidities according to CCI criteria | |
| Diabetes mellitus, n (%) | 119 (23.1) |
| Arterial hypertension, n (%) | 284 (55.2) |
| Atrial fibrillation, n (%) | 156 (30.3) |
| CKD with eGFR < 60 mL/min/1.73 m2, n (%) | 192 (37.3) |
| History of acute myocardial infarction, n (%) | 206 (40) |
| Peripheral vascular disease, n (%) | 51 (9.1) |
| Cerebrovascular disease or TIA, n (%) | 28 (5.4) |
| Chronic obstructive pulmonary disease, n (%) | 46 (8.9) |
| Liver disease, n (%) | 15 (2.9) |
| Charlson Comorbidity Index, mean (SD) | 4.4 (2.3) |
| 0–2, n (%) | 108 (21) |
| 3–4, n (%) | 171 (33.2) |
| ≥ 5, n (%) | 236 (45.8) |
| Implanted device | |
| Single-chamber ICD, n (%) | 114 (22.1) |
| Dual-chamber ICD, n (%) | 165 (32) |
| CRT-D, n (%) | 198 (38.4) |
| Subcutaneous ICD, n (%) | 38 (7.4) |
| Primary prevention indication, n (%) | 376 (73) |
| Ejection fraction in %, median (IQR) | 33 (32–40) |
| Baseline characteristics . | All (n = 515) . |
|---|---|
| Demographics | |
| Age at implant (years), median (IQR) | 68.8 (59.6–75.4) |
| <50, n (%) | 45 (8.7) |
| 50–59, n (%) | 79 (15.3) |
| 60–69, n (%) | 130 (25.1) |
| 70–79, n (%) | 177 (34.4) |
| ≥ 80, n (%) | 84 (16.3) |
| Male sex, n (%) | 404 (78.5) |
| BMI (kg/m2), median (IQR) | 26.7 (24–30.5) |
| BMI < 18.5 kg/m2, n (%) | 14 (2.9) |
| BMI > 30 kg/m2, n (%) | 135 (28.2) |
| Ischemic cardiomyopathy | 275 (53.5) |
| Haemodialysis, n (%) | 3 (0.6%) |
| Comorbidities according to CCI criteria | |
| Diabetes mellitus, n (%) | 119 (23.1) |
| Arterial hypertension, n (%) | 284 (55.2) |
| Atrial fibrillation, n (%) | 156 (30.3) |
| CKD with eGFR < 60 mL/min/1.73 m2, n (%) | 192 (37.3) |
| History of acute myocardial infarction, n (%) | 206 (40) |
| Peripheral vascular disease, n (%) | 51 (9.1) |
| Cerebrovascular disease or TIA, n (%) | 28 (5.4) |
| Chronic obstructive pulmonary disease, n (%) | 46 (8.9) |
| Liver disease, n (%) | 15 (2.9) |
| Charlson Comorbidity Index, mean (SD) | 4.4 (2.3) |
| 0–2, n (%) | 108 (21) |
| 3–4, n (%) | 171 (33.2) |
| ≥ 5, n (%) | 236 (45.8) |
| Implanted device | |
| Single-chamber ICD, n (%) | 114 (22.1) |
| Dual-chamber ICD, n (%) | 165 (32) |
| CRT-D, n (%) | 198 (38.4) |
| Subcutaneous ICD, n (%) | 38 (7.4) |
| Primary prevention indication, n (%) | 376 (73) |
| Ejection fraction in %, median (IQR) | 33 (32–40) |
BMI, body mass index; CCI, Charlson Comorbidity Index; CKD, chronic kidney disease; CRT-D, cardiac resynchronization therapy and defibrillator; ICD, implantable cardioverter defibrillator; IQR, interquartile range; SD, standard deviation; TIA, transitory ischaemic attack.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
